Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

RLYB

Rallybio Corp

Last Close
May 17 • 04:00PM ET
1.77
Dollar change
-0.09
Percentage change
-4.84 		%
Held by: IWM VTI IWN VXF VTWO IWC VTWV AVSC URTY VTHR
IndexRUT P/E- EPS (ttm)-1.88 Insider Own46.38% Shs Outstand37.83M Perf Week-3.28%
Market Cap73.37M Forward P/E- EPS next Y-1.39 Insider Trans0.00% Shs Float22.22M Perf Month5.99%
Income-76.28M PEG- EPS next Q-0.37 Inst Own33.24% Short Float8.81% Perf Quarter-11.50%
Sales0.00M P/S- EPS this Y17.97% Inst Trans0.44% Short Ratio1.22 Perf Half Y-24.20%
Book/sh2.36 P/B0.75 EPS next Y7.83% ROA-58.30% Short Interest1.96M Perf Year-68.62%
Cash/sh2.27 P/C0.78 EPS next 5Y- ROE-62.43% 52W Range1.23 - 9.14 Perf YTD-25.94%
Dividend Est.- P/FCF- EPS past 5Y-35.52% ROI-85.44% 52W High-80.63% Beta-1.60
Dividend TTM- Quick Ratio9.77 Sales past 5Y0.00% Gross Margin- 52W Low44.49% ATR (14)0.18
Dividend Ex-Date- Current Ratio9.77 EPS Y/Y TTM8.67% Oper. Margin0.00% RSI (14)47.67 Volatility7.62% 8.43%
Employees43 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price13.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-8.46% Payout- Rel Volume0.13 Prev Close1.86
Sales Surprise- EPS Surprise0.72% Sales Q/Q- EarningsMay 09 BMO Avg Volume1.60M Price1.77
SMA20-2.48% SMA50-0.17% SMA200-38.98% Trades Volume205,758 Change-4.84%
Date Action Analyst Rating Change Price Target Change
May-15-24Downgrade JP Morgan Overweight → Neutral
Feb-07-24Downgrade Jefferies Buy → Hold $7 → $1.50
Apr-17-23Initiated H.C. Wainwright Buy $18
Apr-10-23Initiated Wedbush Outperform $17
Dec-09-22Initiated JP Morgan Overweight $21
Feb-22-22Initiated JMP Securities Mkt Outperform $32
Aug-23-21Initiated Jefferies Buy $20
Aug-23-21Initiated Evercore ISI Outperform $40
Aug-23-21Initiated Cowen Outperform
May-10-24 06:30AM
3 Biotech Stocks to Sell in May Before They Crash & Burn
(InvestorPlace)
May-09-24 01:54PM
RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024
(InvestorPlace)
10:14AM
Rallybio reins in preclinical R&D, while Monopar pivots to radiopharma to eke out cash
(FierceBiotech.com)
08:00AM
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
(Business Wire)
May-07-24 08:00AM
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
(Business Wire)
04:01PM Loading…
Apr-17-24 04:01PM
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
(Business Wire)
Apr-12-24 10:23AM
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
(Zacks) -26.17%
Apr-11-24 07:43AM
Why Is Rallybio (RLYB) Stock Up 93% Today?
(InvestorPlace) +82.82%
Apr-10-24 04:01PM
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
(Business Wire)
01:01PM
J&J, Rallybio partner on drug development for rare fetal condition
(BioPharma Dive)
Apr-01-24 10:05AM
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
(Business Wire)
Mar-12-24 08:00AM
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
(Business Wire) -8.70%
Feb-26-24 08:00AM
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
(Business Wire) +5.88%
Feb-06-24 09:46AM
Rallybio, with financial fuel levels falling, loses 45% of workforce to extend cash runway into 2026
(FierceBiotech.com) +24.00%
08:00AM
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
(Business Wire)
08:00AM Loading…
Jan-04-24 08:00AM
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
(Business Wire)
Dec-20-23 08:00AM
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
(Business Wire) -5.50%
Dec-09-23 12:00PM
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
(Business Wire)
Nov-28-23 07:00AM
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
(Business Wire) -10.00%
Nov-09-23 08:00AM
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
(Business Wire)
Nov-08-23 08:00AM
Rallybio to Present at Upcoming Investor Conferences in November
(Business Wire) -12.79%
Nov-02-23 09:15AM
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
(Business Wire)
Oct-03-23 08:00AM
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
(Business Wire) +10.14%
Sep-03-23 12:00PM
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
(Business Wire)
Aug-31-23 08:00AM
Rallybio to Present at Upcoming Investor Conferences in September
(Business Wire)
Aug-08-23 08:00AM
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
(Business Wire)
Aug-02-23 08:00AM
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
(Business Wire)
Jul-11-23 08:00AM
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
(Business Wire)
Jun-29-23 07:00AM
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
(Business Wire) -5.57%
Jun-24-23 03:30PM
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
(Business Wire)
09:15AM Loading…
Jun-09-23 09:15AM
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
(Business Wire)
Jun-01-23 08:00AM
Rallybio to Present at the Jefferies Healthcare Conference
(Business Wire) +6.01%
May-29-23 09:55AM
Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade
(Zacks)
May-12-23 09:55AM
Does Rallybio Corporation (RLYB) Have the Potential to Rally 290.63% as Wall Street Analysts Expect?
(Zacks)
May-09-23 08:00AM
Rallybio Reports First Quarter 2023 Financial Results
(Business Wire) -7.00%
May-08-23 08:00AM
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
(Business Wire) +6.57%
Apr-06-23 08:00AM
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
(Business Wire)
Apr-03-23 08:00AM
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
(Business Wire)
Mar-15-23 09:15AM
We're Not Very Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Rate
(Simply Wall St.)
Mar-10-23 09:35AM
Down -19.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Rallybio Corporation (RLYB)
(Zacks)
Mar-06-23 02:49PM
Rallybio Pulls Plug On One Candidate After Highlighting Encouraging Data From Another Thrombocytopenia Program
(Benzinga) +10.34%
08:00AM
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
(Business Wire)
07:30AM
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
(Business Wire)
Mar-02-23 09:01AM
EyePoint Pharma Takes $20.7M Intangible Impairment Charge In Q4, Shares Pipeline Update, Expects Cash Runway Into 2024
(Benzinga)
Mar-01-23 08:00AM
Rallybio to Present at Upcoming Investor Conferences in March
(Business Wire)
Feb-27-23 07:00AM
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybios Inhibitor of Complement Component 5 (C5) and EyePoints Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
(Business Wire)
Jan-31-23 04:05PM
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
(Business Wire)
Jan-05-23 08:00AM
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
(Business Wire)
Dec-15-22 08:00AM
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
(Business Wire) +11.25%
Dec-14-22 06:39AM
Rallybio Corporation (NASDAQ:RLYB) insiders are still down US$129k after purchasing last year, recent gain helped regain some losses
(Simply Wall St.) +6.95%
Dec-12-22 05:55PM
2 Strong Buy Stocks J.P. Morgan Predicts Will Surge Over 50%
(TipRanks) -5.27%
Dec-01-22 07:00AM
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
(Business Wire)
Nov-29-22 08:00AM
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
(Business Wire) -7.53%
Nov-17-22 05:39AM
Private equity firms who have a significant stake must be disappointed along with institutions after Rallybio Corporation's (NASDAQ:RLYB) market cap dropped by US$54m
(Simply Wall St.) +7.65%
Nov-11-22 08:00AM
Rallybio to Present at Upcoming Investor Conferences in November
(Business Wire) -16.57%
Nov-10-22 11:51PM
Rallybio Announces Pricing of $50 Million Public Offering
(Business Wire) -16.56%
09:15AM
Rallybio Announces Proposed Public Offering
(Business Wire)
Nov-07-22 08:00AM
Rallybio Reports Third Quarter 2022 Financial Results
(Business Wire)
07:30AM
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
(Business Wire)
Oct-06-22 08:38AM
Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.) +5.26%
Sep-28-22 12:37PM
Rallybio's Thrombocytopenia Candidate Shows Rapid, Complete Elimination Of Transfused Platelets
(Benzinga)
08:00AM
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
(Business Wire)
Aug-31-22 08:00AM
Rallybio to Present at the 2022 Wells Fargo Healthcare Conference
(Business Wire)
Aug-08-22 08:00AM
Rallybio Reports Second Quarter 2022 Financial Results
(Business Wire) -5.78%
Aug-02-22 08:00AM
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
(Business Wire)
Jul-06-22 07:37AM
Multiple insiders bought Rallybio Corporation (NASDAQ:RLYB) stock earlier this year, a positive sign for shareholders
(Simply Wall St.)
Jun-02-22 08:30AM
Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer
(Business Wire)
Jun-01-22 08:00AM
Rallybio to Present at Upcoming Investor Conferences in June
(Business Wire)
May-10-22 08:00AM
Rallybio Reports First Quarter 2022 Financial Results
(Business Wire) +6.05%
07:30AM
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
(Business Wire)
Apr-29-22 08:36AM
We're Hopeful That Rallybio (NASDAQ:RLYB) Will Use Its Cash Wisely
(Simply Wall St.)
Apr-28-22 11:45AM
10 Best Stocks Under $20 According to Billionaire Andreas Halvorsens Viking Global
(Insider Monkey)
Apr-04-22 08:00AM
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
(Business Wire) +7.03%
Mar-15-22 08:00AM
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
(Business Wire) -10.56%
Feb-28-22 08:00AM
Rallybio to Present at the Cowen 42nd Annual Health Care Conference
(Business Wire) -5.09%
Jan-27-22 08:49AM
Great news for Rallybio Corporation (NASDAQ:RLYB): Insiders acquired stock in large numbers last year
(Simply Wall St.) +6.80%
Jan-18-22 08:00AM
Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate Communications
(Business Wire) -6.09%
Jan-06-22 08:00AM
Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022
(Business Wire) +6.76%
Dec-30-21 05:33AM
Rallybio (RLYB) Sees Hammer Chart Pattern: Time to Buy?
(Zacks)
Dec-08-21 07:38PM
Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ...
(GuruFocus.com)
07:38PM
Tekla Healthcare Opportunities Fund Buys Moderna Inc, IDEXX Laboratories Inc, Sarepta ...
(GuruFocus.com)
07:38PM
Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ...
(GuruFocus.com)
Dec-01-21 07:26AM
Rallybio (RLYB) Sees Hammer Chart Pattern: Time to Buy?
(Zacks) -8.00%
07:00AM
Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
(Business Wire)
Nov-24-21 08:00AM
Rallybio Corporation to Present at the 4th Annual Evercore ISI HealthCONx Conference
(Business Wire)
Nov-11-21 08:00AM
Rallybio to Present at the Jefferies London Healthcare Conference
(Business Wire) -12.10%
Nov-10-21 07:00AM
Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights
(Business Wire) +5.07%
Oct-29-21 10:49AM
We're Not Very Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Rate
(Simply Wall St.) +6.12%
Sep-09-21 07:00AM
Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights
(Business Wire)
Aug-02-21 04:05PM
Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
(Business Wire) +5.88%
Jul-28-21 09:10PM
Rallybio Corporation Announces Pricing of Initial Public Offering
(Business Wire)
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

SLRX

Salarius Pharmaceuticals Inc

Last Close
May 17 • 04:00PM ET
0.4945
Dollar change
+0.0046
Percentage change
0.94 		%
Held by: MEDX VXF
Index- P/E- EPS (ttm)-2.71 Insider Own6.08% Shs Outstand4.78M Perf Week-1.10%
Market Cap2.36M Forward P/E- EPS next Y-23.50 Insider Trans0.00% Shs Float4.49M Perf Month2.00%
Income-8.92M PEG- EPS next Q-6.70 Inst Own4.06% Short Float1.64% Perf Quarter-14.68%
Sales0.00M P/S- EPS this Y-597.92% Inst Trans-3.15% Short Ratio0.63 Perf Half Y-33.09%
Book/sh0.85 P/B0.58 EPS next Y12.31% ROA-119.38% Short Interest0.07M Perf Year-65.42%
Cash/sh0.91 P/C0.54 EPS next 5Y- ROE-193.68% 52W Range0.43 - 1.87 Perf YTD-23.92%
Dividend Est.- P/FCF- EPS past 5Y64.97% ROI-244.34% 52W High-73.55% Beta1.04
Dividend TTM- Quick Ratio3.91 Sales past 5Y-7.25% Gross Margin- 52W Low15.00% ATR (14)0.04
Dividend Ex-Date- Current Ratio3.91 EPS Y/Y TTM80.15% Oper. Margin0.00% RSI (14)49.04 Volatility7.70% 7.93%
Employees2 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price3.25
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q81.69% Payout- Rel Volume0.35 Prev Close0.49
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMar 22 AMC Avg Volume117.48K Price0.49
SMA20-0.11% SMA50-6.25% SMA200-24.53% Trades Volume40,974 Change0.94%
Date Action Analyst Rating Change Price Target Change
Apr-27-20Initiated Ladenburg Thalmann Buy $3.80
May-13-24 10:53PM
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024
(InvestorPlace)
04:43PM
Salarius: Q1 Earnings Snapshot
(Associated Press Finance)
Mar-22-24 09:52PM
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023
(InvestorPlace) +5.96%
04:34PM
Salarius: Q4 Earnings Snapshot
(Associated Press Finance)
04:05PM
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
(GlobeNewswire)
08:00AM Loading…
Feb-22-24 08:00AM
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
(GlobeNewswire)
Jan-16-24 08:00AM
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
(GlobeNewswire)
Jan-03-24 08:30AM
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
(GlobeNewswire)
Nov-10-23 05:03AM
Salarius: Q3 Earnings Snapshot
(Associated Press Finance)
Nov-07-23 08:30AM
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
(GlobeNewswire)
Aug-10-23 05:10PM
Salarius: Q2 Earnings Snapshot
(Associated Press Finance) -9.32%
04:05PM
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
Aug-09-23 07:39AM
SLRX Pursuing Strategic Alternatives
(Zacks) -9.96%
Aug-08-23 04:05PM
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
(GlobeNewswire)
Jul-11-23 09:00AM
SLRX Continues Cancer Fight with Phase I Trial Approval
(Zacks) -12.41%
08:30AM Loading…
08:30AM
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
(GlobeNewswire)
Jun-12-23 08:00AM
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
(GlobeNewswire)
May-16-23 04:05PM
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire)
May-12-23 08:00AM
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
(GlobeNewswire)
May-11-23 08:20AM
Salarius: Q1 Earnings Snapshot
(AP Finance) -5.41%
08:00AM
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
May-09-23 08:00AM
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
(GlobeNewswire) -16.20%
07:34AM
SLRX: Fighting Cancer Through Two Paths
(Zacks Small Cap Research)
May-01-23 08:30AM
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164
(GlobeNewswire)
Apr-20-23 08:30AM
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting
(GlobeNewswire) -10.75%
Apr-04-23 04:02PM
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
(GlobeNewswire) -12.32%
12:00PM
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023
(GlobeNewswire)
Mar-27-23 08:30AM
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Mar-15-23 11:00AM
Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting
(GlobeNewswire)
Mar-07-23 08:00AM
Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia
(GlobeNewswire)
08:30AM Loading…
Feb-16-23 08:30AM
Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas
(GlobeNewswire)
Jan-27-23 08:30AM
Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
(GlobeNewswire) -5.47%
Jan-19-23 08:30AM
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
(GlobeNewswire) +52.99%
Jan-05-23 08:00AM
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
(GlobeNewswire)
Dec-13-22 08:01AM
Investigators Present Clinical Data on Salarius Pharmaceuticals Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting
(GlobeNewswire) -5.32%
08:00AM
Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting
(GlobeNewswire)
Dec-08-22 08:00AM
Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH
(GlobeNewswire)
Dec-01-22 08:00AM
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire) -5.18%
Nov-10-22 08:30AM
Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Nov-03-22 09:57AM
Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting
(GlobeNewswire)
Oct-27-22 08:30AM
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference
(GlobeNewswire) -14.40%
Oct-19-22 08:30AM
Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference
(GlobeNewswire) -15.73%
Oct-18-22 08:30AM
Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire) -45.18%
Oct-14-22 08:43AM
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split
(GlobeNewswire) -13.81%
Sep-20-22 12:00PM
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
(GlobeNewswire)
Sep-13-22 08:00AM
Salarius Pharmaceuticals CEO Issues Letter to Stockholders
(GlobeNewswire) +10.10%
Aug-22-22 08:30AM
Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewings Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire) -9.29%
Aug-08-22 08:30AM
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire) +9.95%
Aug-04-22 08:30AM
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire)
Aug-02-22 08:30AM
Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
(GlobeNewswire) -6.07%
Jul-29-22 09:15AM
Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022
(GlobeNewswire)
Jun-09-22 07:33AM
Salarius Pharmaceuticals to Participate in BIO International Convention 2022
(GlobeNewswire)
May-18-22 04:10PM
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
(GlobeNewswire) +20.62%
May-12-22 04:05PM
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
(GlobeNewswire) +38.75%
May-11-22 04:05PM
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration
(GlobeNewswire) -16.93%
May-05-22 07:30AM
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress
(GlobeNewswire)
Apr-22-22 08:30AM
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
(GlobeNewswire) -20.54%
Mar-10-22 04:05PM
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results
(GlobeNewswire) +33.40%
Mar-03-22 07:31AM
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress
(GlobeNewswire)
Feb-17-22 08:01AM
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
(GlobeNewswire)
Feb-15-22 09:00AM
Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022
(GlobeNewswire)
Feb-08-22 08:00AM
Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference
(GlobeNewswire)
Feb-03-22 07:30AM
Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program
(GlobeNewswire)
Jan-14-22 01:52PM
Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition
(American City Business Journals)
Jan-13-22 07:00AM
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
(GlobeNewswire)
Jan-06-22 12:45PM
Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022"
(GlobeNewswire) -6.06%
Dec-29-21 08:03AM
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
(GlobeNewswire) -6.19%
Dec-20-21 08:35AM
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
(PR Newswire)
Dec-15-21 08:31AM
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
(GlobeNewswire)
Dec-14-21 08:35AM
Virtual Conference for Life Sciences Companies Broadcast Live December 16th
(PR Newswire)
Nov-29-21 08:01AM
Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference
(GlobeNewswire)
Nov-04-21 04:05PM
Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
(GlobeNewswire)
Oct-28-21 03:06PM
Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know
(Zacks)
Oct-26-21 08:01AM
Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress
(GlobeNewswire)
Oct-07-21 09:05AM
Salarius Pharmaceuticals and Nationwide Childrens Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Oct-05-21 08:01AM
Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference
(GlobeNewswire)
Sep-30-21 04:35PM
Salarius Pharmaceuticals and Nationwide Childrens Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Sep-28-21 07:01AM
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
(GlobeNewswire)
Sep-27-21 08:03AM
Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference
(GlobeNewswire) -5.22%
Sep-22-21 07:33AM
Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership
(GlobeNewswire)
Sep-20-21 08:35AM
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
(GlobeNewswire)
07:33AM
Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index
(GlobeNewswire)
Sep-15-21 08:03AM
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
(GlobeNewswire)
Sep-10-21 08:35AM
Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th
(GlobeNewswire)
Sep-08-21 08:13AM
Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
(GlobeNewswire)
Aug-12-21 02:00PM
Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational
(GlobeNewswire)
09:00AM
Diamond Equity Research Emerging Growth Invitational Summer 2021 Spotlight Virtual Conference
(GlobeNewswire)
Aug-10-21 06:16AM
Here's Why We're Not Too Worried About Salarius Pharmaceuticals' (NASDAQ:SLRX) Cash Burn Situation
(Simply Wall St.)
Aug-05-21 07:32AM
Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
(GlobeNewswire)
Jul-29-21 07:33AM
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
(GlobeNewswire)
Jul-14-21 08:05AM
Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit
(GlobeNewswire)
Jul-13-21 07:33AM
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
(GlobeNewswire)
Jul-09-21 07:33AM
Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
(GlobeNewswire) +7.92%
Jun-17-21 08:03AM
REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
(GlobeNewswire)
Jun-15-21 07:30AM
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
(GlobeNewswire)
Jun-10-21 01:30PM
Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
(GlobeNewswire)
Jun-07-21 07:35AM
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstats Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
(GlobeNewswire)
May-19-21 05:01PM
Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
(GlobeNewswire) -6.21%
May-12-21 04:05PM
Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights
(GlobeNewswire)
02:45PM
Salarius Pharmaceuticals Inc to Host Earnings Call
(ACCESSWIRE)
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.